FDA Approves Vyalev for Adults Living with Advanced Parkinson’s Disease
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD).
- PD is a progressive and chronic movement disorder resulting in tremor, muscle rigidity, slowness of movement and difficulty with balance resulting from the loss of dopamine-producing brain cells.
- Timing for a patient’s access to Vyalev is dependent on their individual insurance plan. Coverage for Medicare patients is expected in the second half of 2025.
- The majority of adverse reactions (ARs) with Vyalev were non-serious and mild or moderate in
severity.
